Pipeline Agenda

ASENT 2017 PIPELINE ORAL SESSION

Chairs: Kathleen Clarence-Smith, MD, PhD, Maral Mouradian, MD, Roger Porter, MD, Amir Tamiz PhD

9:00-9:10

Introduction

K. Clarence-Smith and Co-Chairs

 

9:10-9:20

RIV-5061, A Novel Pro-Cognitive-Anxiolytic Therapy

Doug Cowart, PhD

 

9:20-9:30

High Dose Biotin for Multiple Sclerosis

F. Sedel, MD, PhD

CEO, MedDay Pharmaceuticals

9:30-9:40

Orally-Active, Dual-Mechanism, Functional Selectivity CNS Ligands as Prospective Alzheimer’s Disease-Modifying Therapeutics

John A. Schetz, PhD

Professor of Pharmacology, Neuroscience & Medical Education, Center for Neuroscience Discovery, Institute for Healthy Aging, University of North Texas Health Science Center

9:40- 9:50

Phase II Study to Assess Safety and Target Engagement of AMX0035 in Alzheimer's Disease.

Kent Leslie

CSO,
Amylyx Pharmaceuticals

9:50-10:00

Stereopure Nucleic Acid Therapies in Development for the Treatment of Genetic Neurological Diseases

Michael Panzara, MD, MPH

Franchise Lead, Neurology
Wave Life Sciences

10:00- 10:10

HTT-AS suppression of HTT: A Potential Therapeutic Approach for Huntington's Disease

Pan Li, PhD

Russell Margolis’s Laboratory
Johns Hopkins School of Medicine

10:10-10:20

RNA trans-splicing:  A gene Reprograming Technology with Major Advantages over CRISPR for the Development of Neurotherapeutics

Lloyd Mitchell, MD

CEO and CSO
Retro Therapy

10:20-10:40

Overview of the TAU (temporary authorization of use) Process that allows accelerated access to the market  in France for products meeting a major medical need

Frederic Sedel, MD, PhD

CEO,
MedDay Pharmaceuticals
96 Boulevard Haussmann
75008 Paris

10:40- 10:50

Break

 

10:50-11:00

Nanodendrimer Therapy for Adrenoleukodystrophy

Ali Fatemi,
MD, MBA

Director, Moser Center for Leukodystrophies and Neurogenetics Service 
Associate Professor of Neurology & Pediatrics
Kennedy Krieger Institute 

11:00-11:10

Breaking the Code of Fragile X Syndrome – Pathophysiology, Biomarkers, and Therapeutic(s).

Hao Chen, PhD

CEO
DRI Biosciences Corporation

11:10-11:20

Lisuride sc Continuous Infusion for Parkinsons's Disease

Reinhard Horowski, MD

CEO,
ARAMON Pharma UG

11:20-1130

Novel treatment of Chronic Pain

Gerhard Koenig, PhD

CEO
Quartet Medicine

11:30-12:00

Drug Chess - Thinking a Few Moves Ahead: Explore a series of neurology landscape maps with a life sciences investor to see promising R&D programs in the context of both their competition as well as complementary innovation. To succeed, large companies must work with small ones to develop multiple therapeutic approaches that anticipate all possible moves on the board.

Peter Kolchinsky, PhD

Managing Director,
RA Capital Management, LLC

1:50-2:00

Pairnomix:  Personalized Genetic Evaluations

Matthew Fox

CEO
Pairnomix, LLC

2:00-2:10

Saffron Crocins for Prevention of and Rescue from Retinal Neurodegeneration

JP Sangiovanni, Sc.D

Consultant
Davis Laboratories

2:10-2:20

Magnetically Enhanced Diffusion of tPA for the Treatment of Stroke

Sean C. Morris

CEO
Pulse Therapeutics

2:20- 2:30

Syringe-injectable Mesh Electronics: Stable Long-term Brain Electrophysiology for Neurotherapeutics and Neuroprosthesis

Tian-Ming Fu

Department of Chemistry and Chemical Biology, Harvard University

2:30-2:50

Regulatory trends in regenerative medicine in Japan

Dr. Ken Sakushima

Advanced Review with Electronic Data Promotion Group, PMDA

2:50-3:00

Defent™ ADTF Patch: Deterring Opioid Misuse & Abuse

Steve Damon

CEO
4P Therapeutics

3:00-3:10

Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment For Cannabis Dependence: A Pilot Randomized Clinical Trial

Jose Trigo, PhD

Project Scientist
Translational Addition Research Laboratory
Centre for Addition and Mental Health

3:10-3:20

Development of a Recombinant Molecular Vehicle for Intra-Neuronal Delivery of Antibody Fusion Proteins

Philip Band, PhD

CEO,
Cytodel

3:20- 3:40

Regulatory Innovations in Neurological Disorder Therapies, Including Spinraza and Eteplirsen

F. Sasinowski,  M.S., M.P.H., J.D.

Director
Hyman Phelps and McNamara